Navigation Links
GEA Process Engineering and G-CON Manufacturing Announce PCMM Collaboration with Pfizer
Date:9/24/2013

(PRWEB) September 24, 2013

GEA Process Engineering and G-CON Manufacturing announced today that they have entered into a PCMM (Portable Continuous Miniature & Modular) manufacturing collaboration with Pfizer Inc. with the aim of developing the next generation of oral solid dose (OSD) processing technologies to address the rapidly changing requirements of pharmaceutical development and manufacturing. This collaboration brings together three companies with leading capabilities in product development and manufacturing, OSD processing equipment, and portable, self-contained Good Manufacturing Practice (GMP) facility modules, known as “PODs.” A preliminary engineering study has already been completed, and the new collaboration will focus on the fabrication and qualification of a prototype unit.

“We are very enthusiastic to be working with Pfizer, a leading multinational pharmaceutical corporation, and G-CON to develop a turnkey solution for a continuous and portable manufacturing system,” says Jan Vugts, Managing Director, GEA Pharma Systems. “This project is another milestone in the advancement of the GEA Process Engineering Continuous Manufacturing activities in pharmaceuticals. It builds on the experience of Pfizer and GEA in Real Time Release and has the capability to set the next standard for OSD manufacturing.”

The goal of the collaboration is to create a system that integrates small footprint, continuous/semi-continuous processing equipment, smart control systems, and PODs to process active pharmaceutical ingredient (API) powders and inactive ingredients through to bulk tablets or capsules. PODs, which are portable and can be rapidly deployed, are a cost-effective alternative to large, highly capitalized manufacturing facilities with fixed equipment and limited flexibility. "G-CON's team is very excited to be part of this project and to again demonstrate the flexibility and quality of our autonomous cleanroom POD systems, this time in a solid dosage form application," states Maik Jornitz, Chief Operating Officer, G-CON Manufacturing LLC. "We are privileged to work with Pfizer and GEA and look forward to achieving the goals of the consortium."

This first-of-a-kind system would have the potential to transform the future of pharmaceutical process development and manufacturing while providing the flexibility needed to address the evolving portfolio requirements for in-country and small-lot manufacturing. Additionally, it would have the potential to allow product development, clinical supply manufacture, and commercialization to take place using identical processing equipment, thereby simplifying process transfer, eliminating scale-up and significantly reducing API consumption during the development process. The platform would ultimately have the potential to support a fast-response, low- inventory supply chain as well.

Upon successful completion of this initiative, GEA and G-CON will work with Pfizer to deploy this complete solution of components and the POD facility globally.

“This new OSD manufacturing paradigm will achieve significant cost savings and simplified technology transfer/scale-up from R&D to commercial manufacturing,” said Rod MacKenzie, Senior Vice President and Head of PharmaTherapeutics R&D at Pfizer. “Using the same equipment for development, clinical supplies, and commercial production is expected to maximize efficiencies in manufacturing across the enterprise.”

To more rapidly advance and develop this vision, Pfizer, GEA and G-CON will further explore opportunities to partner with additional, interested companies.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11155867.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. The Aurora Clinic Now Offering Simplified Process for Medical Marijuana Qualification
2. Personalized Medicine Makes Its Way to Pets With Cancer: Morphogenesis and SEVO-Med Team up for a Canine Cancer Field Study, First of Its Kind, Side-Effect-Free Process to Treat Companion Animals
3. Natural Acne Remedy, Probiotic Action Shares Industry Insight on the Correlation between Processed Foods and Acne
4. White Mountain Process' New Whisper Technology Creates World's Only Squeal-less Mechanical Seal
5. Synthetic Biologics Initiates Manufacturing Process for C. difficile Infectious Disease Program
6. Process Analytical Technology/Quality by Design – Keeping An Eye on Your Quality, New Life Science Webinar Hosted by Xtalks
7. Genedata at ESACT Announces Expansion Into Biopharma Process Development
8. Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty
9. Verenium Announces Appointment Of Brian Carter As Vice President Of Grain Processing
10. New 1-step process for designer bacteria
11. Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... advised by its major shareholders, Clean Technology Fund I, ... United States based venture capital funds which ... Biorem (on a fully diluted, as converted basis), that ... of their entire equity holdings in Biorem to TUS ...
(Date:6/27/2016)... ... ... Parallel 6 , the leading software as a service (SaaS) provider ... Patient Encounter CONSULT module which enables both audio and video telemedicine communication between the ... the CONSULT module, patients and physicians can schedule a face to face virtual patient ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
Breaking Biology Technology:
(Date:6/9/2016)... innovation leader in attendance control systems is proud to announce the introduction of fingerprint ... sure the right employees are actually signing in, and to even control the opening ... ... ... Photo ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:5/24/2016)... May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology ... LCD display is the latest premium product recently added to the range of products ... ... ... 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):